Page last updated: 2024-11-06

floxuridine and Carcinoma, Renal Cell

floxuridine has been researched along with Carcinoma, Renal Cell in 33 studies

Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.

Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.

Research Excerpts

ExcerptRelevanceReference
" Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma."3.71gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001)
"Floxuridine dosages were escalated to a maximum of 0."2.69Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study. ( Church, CK; DePriest, CB; Honeycutt, PJ; Schulof, RS; Soori, GS; Stark, JJ; Wiemann, MC, 1999)
"Metastatic renal cell carcinoma patients with measurable disease entered the study."2.68Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon. ( Brunetti, I; Cianci, C; Conte, PF; Falcone, A; Giulianotti, PC; Lencioni, M; Mosca, F; Pfanner, E; Ricci, S; Vannucci, L, 1996)
"Metastatic renal cell carcinoma (RCC) is largely chemoresistant."2.67A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma. ( Carroll, PR; Ernest, ML; Frye, JW; Small, EJ; Stagg, RJ; Wilkinson, MJ, 1994)
"The initial dosage was 0."2.67A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma. ( Carroll, PR; Ernest, ML; Frye, JW; Small, EJ; Stagg, RJ; Venook, AP; Wilkinson, MJ, 1993)
"Therapy of metastatic bladder cancer with doxorubicin-cisplatin was made more tolerable by this same circadian approach resulting in a 57% objective response rate."2.41Circadian chemotherapy for gynecological and genitourinary cancers. ( Hrushesky, WJ; Kobayashi, M; Wood, PA, 2002)
"Metastatic renal cell carcinoma has a poor prognosis, requiring systemic therapy, in addition to radical nephrectomy."1.30Chemotherapy with FUDR in the management of metastatic renal cell carcinoma. ( Aveta, P; Cracco, C; Neira, D; Rocca Rossetti, S; Terrone, C, 1997)
"The authors treated 10 advanced renal cell carcinoma with circadian venous continuous infusion of 5-Fluoro 2-Deoxyuridine (FUDR)."1.28[Adjuvant chemotherapy]. ( Buzzetti, V; Cogni, M; Del Nero, A; Longo, G; Mandressi, A; Mangiarotti, B; Russo, R, 1991)
"A total of 42 patients with metastatic renal cell carcinoma received floxuridine infusion for 14 days at monthly intervals."1.28Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. ( Amato, R; Dexeus, FH; Kilbourn, R; Kwan, J; Logothetis, CJ; Newman, RA; Ogden, S; Sella, A; Striegel, A, 1991)
"The authors treated 42 metastatic renal cell carcinoma (RCC) patients who had received no previous chemotherapy or radiation therapy with circadian venous continuous infusion of 5-fluoro-2-deoxyuridine (FUDR)."1.28Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump. ( Bonalumi, MG; Comeri, G; Damascelli, B; Del Nero, A; Garbagnati, F; Lutman, R; Marchianò, A; Mauri, M; Salvetti, M; Spreafico, C, 1990)
"Our results indicate that metastatic renal cell cancer responds to infusional chemotherapy and that the circadian shape of infusion markedly affects our ability to deliver effective doses."1.27Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma. ( Fraley, EE; Hrushesky, WJ; Rabatin, JT; Von Roemeling, R, 1988)

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19903 (9.09)18.7374
1990's21 (63.64)18.2507
2000's9 (27.27)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wang, HJ1
Wang, H1
Li, HZ1
Shi, BB1
Song, ZL1
Stadler, WM2
Ikemoto, S1
Sugimura, K1
Yoshida, N1
Kuratsukuri, K1
Wada, S1
Nakatani, T1
Gore, ME1
Escudier, B1
Chu, SI1
Kim, HJ1
Skubitz, KM1
Wong, MK1
Bjarnason, GA2
Hrushesky, WJ8
Webster, P1
Morava-Protzner, I1
Towers, M1
Small, EJ3
Frye, JW2
Wilkinson, MJ2
Carroll, PR2
Ernest, ML2
Stagg, RJ2
Falcone, A2
Cianci, C2
Ricci, S2
Brunetti, I2
Bertuccelli, M1
Conte, PF2
Conroy, T1
Geoffrois, L1
Guillemin, F1
Luporsi, E1
Krakowski, I1
Spaëth, D1
Frasie, V1
Volff, D1
Venook, AP1
Doyle, N1
Sone, M1
Beattie, K1
Elia, J1
Owens, B1
Garufi, C1
Lévi, F1
Giunta, S1
Aschelter, A1
Pace, R1
Nisticò, C1
Terzoli, E1
Pfanner, E1
Lencioni, M1
Giulianotti, PC1
Vannucci, L1
Mosca, F1
Aveta, P1
Terrone, C1
Neira, D1
Cracco, C1
Rocca Rossetti, S1
Hirano, Y2
Takayama, T2
Ushiyama, T2
Suzuki, K2
Fujita, K2
Soori, GS1
Schulof, RS1
Stark, JJ1
Wiemann, MC1
Honeycutt, PJ1
Church, CK1
DePriest, CB1
Yonekura, K2
Basaki, Y2
Chikahisa, L2
Okabe, S2
Hashimoto, A2
Miyadera, K2
Wierzba, K2
Yamada, Y2
Reese, DM1
Corry, M1
Morita, T1
Matsuzaki, A1
Tokue, A1
Aoyagi, K1
Kobayashi, M1
Wood, PA1
Kageyama, S1
Vogelzang, NJ1
Vokes, EE1
Charette, J1
Whitman, G1
Del Nero, A2
Mandressi, A1
Longo, G1
Cogni, M1
Mangiarotti, B1
Buzzetti, V1
Russo, R1
Dexeus, FH1
Logothetis, CJ1
Sella, A1
Amato, R1
Kilbourn, R1
Ogden, S1
Striegel, A1
Kwan, J1
Newman, RA1
Damascelli, B2
Marchianò, A2
Frigerio, LF1
Salvetti, M2
Spreafico, C2
Garbagnati, F2
Zanoni, F1
Radice, F1
Lutman, R1
Bonalumi, MG1
Mauri, M1
Comeri, G1
von Roemeling, R4
Lanning, RM1
Rabatin, JT3
Fraley, EE2

Reviews

3 reviews available for floxuridine and Carcinoma, Renal Cell

ArticleYear
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.
    Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:6 Suppl 5

    Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II

2006
Circadian chemotherapy for gynecological and genitourinary cancers.
    Chronobiology international, 2002, Volume: 19, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Cycle; Chronotherapy; Circadian Rhythm;

2002
The multifrequency (circadian, fertility cycle, and season) balance between host and cancer.
    Annals of the New York Academy of Sciences, 1991, Volume: 618

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Circadian Rhythm; Female; F

1991

Trials

13 trials available for floxuridine and Carcinoma, Renal Cell

ArticleYear
[Immunotherapy of metastatic renal cell carcinoma: report of 28 cases].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 2004, Feb-22, Volume: 42, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal

2004
A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
    Cancer, 1994, Jun-01, Volume: 73, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administrat

1994
Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study.
    Cancer, 1993, Jul-15, Volume: 72, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Floxurid

1993
Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma.
    Cancer, 1993, Oct-01, Volume: 72, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Circadian Rhythm; Drug Administration Schedul

1993
A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.
    Cancer, 1993, Jun-01, Volume: 71, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Circadian Rhythm; Diarrhea; Drug Administrati

1993
Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.
    The Journal of infusional chemotherapy, 1995, Volume: 5, Issue:3 Suppl 1

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chronobiology Phenom

1995
Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administrat

1996
Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study.
    Cancer investigation, 1999, Volume: 17, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel

1999
Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.
    Cancer chemotherapy and pharmacology, 1992, Volume: 31, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carci

1992
Flexibility and efficacy of automatic continuous fluorodeoxyuridine infusion in metastases from a renal cell carcinoma.
    Cancer, 1991, Sep-01, Volume: 68, Issue:5

    Topics: Brain Neoplasms; Carcinoma, Renal Cell; Circadian Rhythm; Drug Administration Schedule; Drug Evaluat

1991
Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:9

    Topics: Adult; Aged; Carcinoma, Renal Cell; Circadian Rhythm; Female; Floxuridine; Humans; Infusion Pumps; K

1990
Cancer chronotherapy: a drug delivery challenge.
    Progress in clinical and biological research, 1990, Volume: 341A

    Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug

1990
Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:11

    Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Implants

1989

Other Studies

17 other studies available for floxuridine and Carcinoma, Renal Cell

ArticleYear
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
    Der Urologe. Ausg. A, 2004, Volume: 43 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Clinical Trials

2004
Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon-alpha in renal cell carcinoma cell lines.
    Urologia internationalis, 2004, Volume: 73, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce

2004
Pulmonary toxicity of continuous infusion 5-fluoro-2'-deoxyuridine.
    Anti-cancer drugs, 1995, Volume: 6, Issue:3

    Topics: Aged; Carcinoma, Renal Cell; Floxuridine; Humans; Infusions, Intravenous; Kidney Neoplasms; Lung Dis

1995
Steroid-responsive interstitial lung disease in patients receiving 2'-deoxy-5-fluorouridine-infusion chemotherapy. A report of three cases.
    Cancer, 1995, May-15, Volume: 75, Issue:10

    Topics: Aged; Carcinoma, Renal Cell; Cough; Dyspnea; Female; Fever; Floxuridine; Forced Expiratory Volume; H

1995
Formal clinical evaluation of the CADD-Micro system for circadian delivery of FUDR in patients with metastatic renal cell cancer.
    The Journal of infusional chemotherapy, 1995,Spring, Volume: 5, Issue:2

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Circadian Rhythm; Drug Administration Schedu

1995
Chemotherapy with FUDR in the management of metastatic renal cell carcinoma.
    Annales d'urologie, 1997, Volume: 31, Issue:3

    Topics: Actuarial Analysis; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chemotherap

1997
[The correlation between thymidine phosphorylase activity of renal cancer cells and the chemosensitivity to 5-FU and 5'-DFUR].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:11

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Screening Assays

1998
UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:8

    Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cel

1999
Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma.
    Cancer, 2000, Mar-15, Volume: 88, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth

2000
Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
    International journal of cancer, 2001, May-01, Volume: 92, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Cell Survival; Deoxyc

2001
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
    Angiogenesis, 2001, Volume: 4, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc

2001
Thymidine phosphorylase activity in renal cell carcinoma: relationship between histological parameters and chemosensitivity to fluorouracil-related drugs.
    Urological research, 2002, Volume: 30, Issue:2

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Floxuridine; Fluorouracil; Humans; Kidney; K

2002
[Adjuvant chemotherapy].
    Archivio italiano di urologia, nefrologia, andrologia : organo ufficiale dell'Associazione per la ricerca in urologia = Urological, nephrological, and andrological sciences, 1991, Volume: 63, Issue:2

    Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Administration Schedule; Floxuridine; Follow-Up Studies; Hu

1991
Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma.
    The Journal of urology, 1991, Volume: 146, Issue:3

    Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Floxuridine; Humans; Infus

1991
Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump.
    Cancer, 1990, Jul-15, Volume: 66, Issue:2

    Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Evaluation; Female; Floxuridine; Humans; Infusion Pumps, Im

1990
Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusion.
    The Journal of urology, 1988, Volume: 139, Issue:2

    Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Floxuridine; Gastrointestinal Diseases; Humans; Infusion

1988
Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma.
    Seminars in surgical oncology, 1988, Volume: 4, Issue:2

    Topics: Adult; Aged; Carcinoma, Renal Cell; Circadian Rhythm; Dose-Response Relationship, Drug; Female; Flox

1988